- Home
- » Tags
- » Neuropsychopharmacology
Top View
- Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: a Genome-Wide Pharmacogenomics Study ✉ Joanna M
- Acute Toxic Effects of Club Drugs
- Antidepressant Effect of Methanol Root Bark Extract of Acacia Seyal Del
- ACNP Mission Statement
- Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms
- WHO Expert Committee on Drug Dependence Pre-Review ……………
- Selective Kappa-Opioid Antagonism Ameliorates Anhedonic Behavior: Evidence from the Fast-Fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
- Ligand Functional Selectivity Advances Our Understanding of Drug
- The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice
- Key Concepts in Psychopharmacology
- [3H]PD 128907, a Putatively Selective Ligand for the D3 Dopamine Receptor, in Rat Brain: a Receptor Binding and Quantitative Autoradiographic Study Gregory N
- (MDMA, “Ecstasy”) Investigator's Brochure
- The Pharmacology of Psilocybin
- Principles of Neuropsychopharmacology
- Ethanol Potently and Competitively Inhibits Binding of the Alcohol Antagonist Ro15-4513 to ␣4/63␦ GABAA Receptors H
- 5-HT Receptors and the Development of New Antidepressants
- Accepted Manuscript
- Current Concepts and Treatments of Schizophrenia
- Neuroscience-Based Nomenclature (Nbn) for Journal of Psychopharmacology
- Pharmacogenomics at the Point of Care: a Community Pharmacy Project in British Columbia
- Neuropharmacology in the Next Millennium: Promise for Breakthrough Discoveries
- Course Syllabus
- (OPC-14597) with Dopamine and Serotonin Receptor Subtypes Cindy P
- Psychopharmacology & Biological Psychiatry
- Neuropharmacology, 3Rd Edition, C
- Report of the Neuropsychopharmacology Section
- Plant Expression of Cocaine Hydrolase-Fc Fusion Protein for Treatment Of
- Ketamine: Promising Path Or False Prophecy in the Development of Novel Therapeutics for Mood Disorders&Quest;
- Pharmacokinetics, Pharmacodynamics, and Drug Disposition
- Neuropsychopharmacology in the Netherlands
- Antemortem and Postmortem Methamphetamine Blood Concentrations: Three Case Reports
- Pharmacology and Neuroscience Student Handbook 2019-2020
- N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, As a Putative Mediator of Quetiapine’S Antidepressant Activity
- Pharmacogenomic Biomarkers and Their Applications in Psychiatry
- Homogeneous, Real-Time Nanobret Binding Assays for the Histamine H3
- Clinical Psychopharmacology Bibb 482 Syllabus
- Clinical Advances in Non-Agonist Therapies May 11, 2016 Report of Proceedings
- Long-Acting Cocaine Hydrolase for Addiction Therapy
- AN ORAL HISTORY of NEUROPSYCHOPHARMACOLOGY the FIRST FIFTY YEARS Peer Interviews
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
- Depletion of 5-HT Disrupts Prepulse Inhibition in Rats: Dependence on the Magnitude of Depletion, and Reversal by a 5-HT Precursor Eric P
- Central CRH System in Depression and Anxiety — Evidence from Clinical Studies with CRH1 Receptor Antagonists ⁎ Florian Holsboer , Marcus Ising
- A Novel G Protein-Biased and Subtype Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extract
- Neuropsychopharmacology at the New Millennium: New Industry Directions John F
- Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats
- Discovery of Β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy
- A Systemically Administered Neurotensin Agonist Blocks Disruption of Prepulse Inhibition Produced by a Serotonin-2A Agonist
- VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms
- Tracking the Cognitive Pharmacodynamics of Psychoactive Substances with Combinations of Behavioral and Neurophysiological Measures Alan Gevins, D.Sc., Michael E
- Directing Bitopic Or Bivalent Molecules to Dopamine D3 Receptors for the Treatment of Substance Use Disorders
- Neuropsychopharmacology Across Brain Diseases”, Held in Nice, France from 9 to 10 March 2010
- Functional Selective D2 Ligands for the Treatment of Schizophrenia
- Chapter 37: Pharmacogenomics and Personalized Therapeutics In
- D3 Receptor Desensitization and Internalization in Vivo with PET&Sol